Page last updated: 2024-09-04

cox 189 and celecoxib

cox 189 has been researched along with celecoxib in 30 studies

Compound Research Comparison

Studies
(cox 189)
Trials
(cox 189)
Recent Studies (post-2010)
(cox 189)
Studies
(celecoxib)
Trials
(celecoxib)
Recent Studies (post-2010) (celecoxib)
16349475,2738432,428

Protein Interaction Comparison

ProteinTaxonomycox 189 (IC50)celecoxib (IC50)
Chain A, Carbonic anhydrase IIHomo sapiens (human)0.021
Prostaglandin E synthaseHomo sapiens (human)0.4825
Histone deacetylase 3Homo sapiens (human)1.637
Prostaglandin G/H synthase 1 Bos taurus (cattle)7.9667
Prostaglandin G/H synthase 2 Bos taurus (cattle)0.057
Cytochrome c oxidase subunit 1Ovis aries (sheep)6.5
Cytochrome c oxidase subunit 2Ovis aries (sheep)0.0881
Catechol O-methyltransferaseMus musculus (house mouse)0.036
Cytochrome c oxidase subunit 2Homo sapiens (human)0.371
Carbonic anhydrase 1Homo sapiens (human)0.1555
Carbonic anhydrase 2Homo sapiens (human)0.0925
Prostaglandin G/H synthase 1Ovis aries (sheep)5.271
Procathepsin LHomo sapiens (human)0.56
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)7.308
Seed linoleate 13S-lipoxygenase-1Glycine max (soybean)0.07
Polyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)4.295
Cytochrome P450 2D6Homo sapiens (human)1
Cytochrome P450 2C9 Homo sapiens (human)10
Calpain-2 catalytic subunitHomo sapiens (human)0.002
Alpha-2B adrenergic receptorHomo sapiens (human)1.516
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)0.12
Prostaglandin G/H synthase 1Mus musculus (house mouse)3.6401
Prostaglandin G/H synthase 1Homo sapiens (human)3.5499
Sodium-dependent noradrenaline transporter Homo sapiens (human)7.308
Indoleamine 2,3-dioxygenase 1Mus musculus (house mouse)0.006
Sodium-dependent serotonin transporterHomo sapiens (human)6.276
Prostaglandin G/H synthase 2Homo sapiens (human)0.3818
Prostaglandin G/H synthase 2 Rattus norvegicus (Norway rat)0.4028
Urotensin-2 receptorRattus norvegicus (Norway rat)7.6
Histone deacetylase 4Homo sapiens (human)1.637
D(2) dopamine receptorRattus norvegicus (Norway rat)0.03
Prostaglandin G/H synthase 2Ovis aries (sheep)0.6343
Mu-type opioid receptorCavia porcellus (domestic guinea pig)7.7
Sodium-dependent dopamine transporter Homo sapiens (human)2.431
Prostaglandin G/H synthase 2Mus musculus (house mouse)0.045
Histone deacetylase 1Homo sapiens (human)1.411
Mitogen-activated protein kinase 14Homo sapiens (human)0.81
Carbonic anhydrase 9Homo sapiens (human)0.016
Sigma intracellular receptor 2Rattus norvegicus (Norway rat)0.05
Prostaglandin G/H synthase 1 Rattus norvegicus (Norway rat)0.3
Prostaglandin G/H synthase 1Canis lupus familiaris (dog)5.57
Cyclooxygenase-2 Canis lupus familiaris (dog)0.9
Histone deacetylase 7Homo sapiens (human)1.637
Histone deacetylase 2Homo sapiens (human)1.637
Carbonic anhydrase 4Bos taurus (cattle)0.2227
Polyamine deacetylase HDAC10Homo sapiens (human)1.637
Histone deacetylase 11 Homo sapiens (human)1.637
Histone deacetylase 8Homo sapiens (human)1.637
P2Y purinoceptor 12Rattus norvegicus (Norway rat)0.04
Histone deacetylase 6Homo sapiens (human)1.14
Histone deacetylase 9Homo sapiens (human)1.637
Histone deacetylase 5Homo sapiens (human)1.637

Research

Studies (30)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's19 (63.33)29.6817
2010's11 (36.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ekins, S; Williams, AJ; Xu, JJ1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Bhardwaj, A; Dzandzi, J; Tietz, O; Valliant, JF; Wuest, F1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Adami, S; Berenbaum, F; Bliddal, H; Gimona, A; Lee, A; Moore, A; Navarro, F; Poor, G; Reginster, JY; Robinson, J; Tannenbaum, H; Uebelhart, D; Zacher, J1
Fricke, J; Jayawardene, S; Kellstein, D; Ott, D1
Cousin, M; Fiedorowicz-Fabrycy, IF; Gitton, X; Hawkey, CC; Hoexter, G; Nasonov, EL; Pikhlak, EG; Svoboda, P1
Curran, MP; Lyseng-Williamson, KA1
Cristofoletti, R; Fabricio, AS; Navarra, P; Souza, GE; Veiga, FH1
Beaulieu, A; Dutta, D; Paster, Z; Sheldon, E; Sloan, VS; Yu, S1
Brzosko, M; Kopsa, P; Kreisse, A; Lehmann, R; Litschig, S; Nischik, R; Sloan, VS; Thurston, H1
Hochberg, MC1
Dutta, D; Fleischmann, R; Maldonado-Cocco, J; Sheldon, E; Sloan, VS; Yu, S1
Bishop-Bailey, D; Mitchell, JA; Vojnovic, I; Warner, TD1
Burger, KJ; Fashola, TO; Krehan, G; Maeumbaed, R; Runge, H; Schell, E; Schlüter, P; Thurston, HJ; Trechsel, U; Wittenberg, RH1
Marwali, MR; Mehta, JL1
Deray, G; Montalescot, G; Sibilia, J1
Deray, G; Héloire, F; Valat, JP1
Dougados, M; Gitton, X; Moore, A; Yu, S1
Ashcroft, DM; Chen, LC1
Davis, N; Fricke, J; Krammer, G; Yu, V1
Klotz, U; Shi, S1
Fleischmann, R; Notter, M; Patel, NP; Reginster, JY; Sallstig, P; Tannenbaum, H1
Elliott, WJ1
Bakhle, YS; de Francischi, JN; dos Reis, WG; Ferreira-Alves, DL; Gassani, BC; Paiva-Lima, P; Rezende, RM1
Honjo, H; Iwamoto, K; Uwai, Y1
Harirforoosh, S; Pettit, WL; Wyatt, JE1
Hu, RW; Li, HY; Li, JS; Miao, XP; Ouyang, Q; Zhang, Y1
Anstaett, P; Ferrari, S; Gasser, G; Pierroz, V1
Hansen, SH; Skonberg, C; Syed, M1

Reviews

11 review(s) available for cox 189 and celecoxib

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
    Current topics in medicinal chemistry, 2005, Volume: 5, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Membrane Proteins; Organic Chemicals; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Rheumatology; Sulfonamides; Sulfones; Treatment Outcome

2005
COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies.
    Thrombosis and haemostasis, 2006, Volume: 96, Issue:4

    Topics: Animals; Blood Platelets; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Labeling; Endothelium, Vascular; Epoprostenol; Humans; Lactones; Platelet Aggregation; Product Surveillance, Postmarketing; Pyrazoles; Randomized Controlled Trials as Topic; Risk Assessment; Sulfonamides; Sulfones; Thromboxane A2

2006
[What do we know about the cardiovascular toxicity of the NSAIDs?].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Follow-Up Studies; Humans; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors

2006
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No

    Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Diclofenac; Edema; Heart Failure; Humans; Hypertension; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Odds Ratio; Placebos; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors

2006
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.
    Arthritis research & therapy, 2007, Volume: 9, Issue:1

    Topics: Aged; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis; Pain Measurement; Patient Satisfaction; Pyrazoles; Sulfonamides

2007
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
    Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:7

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib; Humans; Isoxazoles; Lactones; Models, Statistical; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones

2007
Clinical use and pharmacological properties of selective COX-2 inhibitors.
    European journal of clinical pharmacology, 2008, Volume: 64, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Monitoring; Etoricoxib; Humans; Osteoarthritis; Pain; Pyrazoles; Pyridines; Sulfonamides; Sulfones

2008
Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?
    Current hypertension reports, 2010, Volume: 12, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Hypertension; Isoxazoles; Lactones; Pyrazoles; Pyridines; Risk; Risk Factors; Sulfonamides; Sulfones

2010
Pharmacogenetics of nonsteroidal anti-inflammatory drugs.
    The pharmacogenomics journal, 2012, Volume: 12, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Aspirin; Celecoxib; Cytochrome P-450 CYP2C9; Diclofenac; Humans; Ibuprofen; Indomethacin; Pharmacogenetics; Pyrazoles; Sulfonamides

2012
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
    The Cochrane database of systematic reviews, 2014, Oct-23, Issue:10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colitis, Ulcerative; Crohn Disease; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Sulfonamides; Sulfones

2014

Trials

11 trial(s) available for cox 189 and celecoxib

ArticleYear
Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.
    Annals of the rheumatic diseases, 2004, Volume: 63, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Humans; Isoenzymes; Logistic Models; Male; Membrane Proteins; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides

2004
Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of post-operative dental pain.
    International journal of clinical practice, 2004, Volume: 58, Issue:3

    Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Humans; Lactones; Male; Molar, Third; Organic Chemicals; Pain, Postoperative; Pyrazoles; Sulfonamides; Sulfones; Tooth Extraction; Treatment Outcome

2004
Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
    The Journal of rheumatology, 2004, Volume: 31, Issue:9

    Topics: Aged; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Female; Humans; Ibuprofen; Incidence; Male; Middle Aged; Organic Chemicals; Osteoarthritis; Peptic Ulcer; Pyrazoles; Risk Factors; Sulfonamides

2004
Lumiracoxib.
    Drugs, 2004, Volume: 64, Issue:19

    Topics: Administration, Oral; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Half-Life; Humans; Male; Molecular Structure; New Zealand; Organic Chemicals; Osteoarthritis; Oxycodone; Pain; Pyrazoles; Sulfonamides; Terminology as Topic; World Health Organization

2004
Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
    Clinical therapeutics, 2005, Volume: 27, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Humans; Male; Membrane Proteins; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome

2005
Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib.
    Current medical research and opinion, 2005, Volume: 21, Issue:4

    Topics: Activities of Daily Living; Administration, Oral; Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Placebos; Pyrazoles; Sulfonamides; Treatment Outcome

2005
Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib.
    Clinical rheumatology, 2006, Volume: 25, Issue:1

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Pain; Pain Measurement; Prospective Studies; Pyrazoles; Sulfonamides; Treatment Outcome

2006
First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].
    Arthritis research & therapy, 2006, Volume: 8, Issue:2

    Topics: Aged; Analgesics; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Pain Measurement; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome

2006
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.
    Arthritis research & therapy, 2007, Volume: 9, Issue:1

    Topics: Aged; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis; Pain Measurement; Patient Satisfaction; Pyrazoles; Sulfonamides

2007
Lumiracoxib 400 mg compared with celecoxib 400 mg and placebo for treating pain following dental surgery: a randomized, controlled trial.
    The journal of pain, 2008, Volume: 9, Issue:1

    Topics: Adolescent; Adult; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Pain Measurement; Pain, Postoperative; Placebo Effect; Pyrazoles; Sulfonamides; Time Factors; Tooth Extraction; Tooth, Impacted; Treatment Outcome

2008
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.
    BMC musculoskeletal disorders, 2008, Mar-07, Volume: 9

    Topics: Aged; Arthralgia; Canada; Cardiovascular Diseases; Celecoxib; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Europe; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Osteoarthritis; Pain Measurement; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome; United States

2008

Other Studies

9 other study(ies) available for cox 189 and celecoxib

ArticleYear
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Design and synthesis of [(125)I]Pyricoxib: A novel (125)I-labeled cyclooxygenase-2 (COX-2) inhibitors.
    Bioorganic & medicinal chemistry letters, 2016, Mar-15, Volume: 26, Issue:6

    Topics: Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Iodine Radioisotopes; Molecular Docking Simulation; Molecular Structure; Pyrimidines; Structure-Activity Relationship; Sulfones

2016
The effects of selective and nonselective cyclooxygenase inhibitors on endothelin-1-induced fever in rats.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2005, Volume: 288, Issue:3

    Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Dinoprost; Dinoprostone; Dose-Response Relationship, Drug; Endothelin-1; Fever; Indomethacin; Injections, Intraperitoneal; Injections, Intraventricular; Intubation, Gastrointestinal; Lipopolysaccharides; Male; Organic Chemicals; Pyrazoles; Rats; Rats, Wistar; Sulfonamides

2005
Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2006, Volume: 20, Issue:3

    Topics: Aspirin; Blood Platelets; Blood Proteins; Calcimycin; Calcium; Celecoxib; Cell Line; Cerebrospinal Fluid Proteins; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Humans; Indomethacin; Ionophores; Lactones; Meloxicam; Naproxen; Organ Specificity; Organic Chemicals; Protein Binding; Pyrazoles; Sodium Salicylate; Sulfonamides; Sulfones; Synovial Fluid; Thiazines; Thiazoles; Thromboxane A2

2006
Is the sulphonamide radical in the celecoxib molecule essential for its analgesic activity?
    Pharmacological research, 2010, Volume: 62, Issue:5

    Topics: Acetazolamide; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Hyperalgesia; Inflammation; Male; Naltrexone; Narcotic Antagonists; Pain; Pain Measurement; Pain Threshold; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides

2010
Inhibitory effect of selective cyclooxygenase-2 inhibitor lumiracoxib on human organic anion transporters hOAT1 and hOAT3.
    Drug metabolism and pharmacokinetics, 2010, Volume: 25, Issue:5

    Topics: Animals; Binding, Competitive; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Estrone; Etoricoxib; Humans; Inhibitory Concentration 50; Isoxazoles; Kinetics; Lactones; Methotrexate; Oocytes; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; p-Aminohippuric Acid; Pyrazoles; Pyridines; RNA, Complementary; Sulfonamides; Sulfones; Xenopus laevis

2010
Two-photon uncageable enzyme inhibitors bearing targeting vectors.
    Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 2015, Volume: 14, Issue:10

    Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Lasers; Photons

2015
Mitochondrial toxicity of selective COX-2 inhibitors via inhibition of oxidative phosphorylation (ATP synthesis) in rat liver mitochondria.
    Toxicology in vitro : an international journal published in association with BIBRA, 2016, Volume: 32

    Topics: Adenosine Triphosphate; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Isoxazoles; Lactones; Male; Mitochondria, Liver; Oxidative Phosphorylation; Pyridines; Rats, Sprague-Dawley; Sulfonamides; Sulfones

2016